|Acura Pharmaceuticals, Inc.|
616 N. North Court
United States - Map
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. Its products include Oxecta Tablets CII, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, an over-the-counter immediate-release pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. The company has seven additional opioid products utilizing Aversion technology in various stages of development. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc., a wholly-owned subsidiary of Pfizer Inc. to develop and commercialize certain opioid analgesic products utilizing the companys proprietary Aversion technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.
|Acura Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jun 1, 2013 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Robert B. Jones ,
Chief Exec. Officer, Pres and Director
|Mr. Peter A. Clemens ,
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
|Dr. Albert W. Brzeczko Ph.D.,
VP of Technical Affairs
|Mr. James F. Emigh R.PH.,
VP of Corp. Devel.
|Mr. Robert A. Seiser ,
VP, Treasurer and Corp. Controller
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|